Bryan T Hennessy
Overview
Explore the profile of Bryan T Hennessy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
8601
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cosgrove N, Fitzpatrick O, Grogan L, Hennessy B, Furney S, Toomey S
Front Oncol
. 2025 Feb;
14:1483126.
PMID: 39935847
Metastatic meningioma is rare, occurring in less than 1% of patients, and very few case studies have been reported, in particular for those that have spread to the lungs. Here...
2.
Geyer Jr C, Untch M, Huang C, Mano M, Mamounas E, Wolmark N, et al.
N Engl J Med
. 2025 Jan;
392(3):249-257.
PMID: 39813643
Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The...
3.
Aslam R, Richards C, Fay J, Hudson L, Workman J, Lee C, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769028
The CDK4/6 inhibitor Ribociclib has shown limited efficacy as a monotherapy in colorectal cancer (CRC). However, combining Ribociclib with targeted therapies could present a viable strategy for treating CRC. This...
4.
Conlon N, Roche S, Mahdi A, Browne A, Breen L, Gaubatz J, et al.
Transl Oncol
. 2024 Aug;
49:102073.
PMID: 39191139
Background: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. Here we report that...
5.
Dowling G, Keelan S, Cosgrove N, Daly G, Giblin K, Toomey S, et al.
Breast Cancer Res Treat
. 2024 Aug;
207(3):471-476.
PMID: 39090418
Purpose: Receptor and subtype discordance between primary breast tumours and metastases is a frequently reported phenomenon. The aim of this article is to review the current evidence on receptor discordance...
6.
Dowling G, Daly G, Hegarty A, Hembrecht S, Bracken A, Toomey S, et al.
Br J Surg
. 2024 Jul;
111(7.
PMID: 39051666
No abstract available.
7.
Stordal B, Farrelly A, Hennessy B
Mol Biol Rep
. 2024 Jun;
51(1):784.
PMID: 38940864
Background: The mutational status of ovarian cancer cell line IGROV-1 is inconsistent across the literature, suggestive of multiple clonal populations of the cell line. IGROV-1 has previously been categorised as...
8.
Dowling G, Daly G, Hegarty A, Hembrecht S, Bracken A, Toomey S, et al.
Br J Surg
. 2024 May;
111(5).
PMID: 38801441
Background: Systemic inflammatory response markers have been found to have a prognostic role in several cancers, but their value in predicting the response to neoadjuvant chemotherapy in breast cancer is...
9.
Thomas V, Rashed A, Faul C, Nicholson S, Young V, Hanson J, et al.
J Pers Med
. 2024 Mar;
14(3).
PMID: 38540999
Up to 15% of lung cancer patients present two or more anatomically separate primary lung lesions, known as multiple primary lung cancers (MPLCs). While surgical resection or stereotactic body radiation...
10.
Tinsley E, Bredin P, Toomey S, Hennessy B, Furney S
Trends Cancer
. 2024 Mar;
10(6):519-530.
PMID: 38453563
KMT2C and KMT2D are histone lysine methyltransferases responsible for the monomethylation of histone 3 lysine 4 (H3K4) residues at gene enhancer sites. KMT2C/D are the most frequently mutated histone methyltransferases...